Colon-targeted engineered postbiotics nanoparticles alleviate osteoporosis through the gut-bone axis.

ABSTRACT: The potential for mitigating intestinal inflammation through the gut-bone axis in the treatment of osteoporosis is significant. While various gut-derived postbiotics or bacterial metabolites have been created as dietary supplements to prevent or reverse bone loss, their efficacy and safety still need improvement. Herein, a colon-targeted drug delivery system is developed using surface engineering of polyvinyl butyrate nanoparticles by shellac resin to achieve sustained release of postbiotics butyric acid at the colorectal site. These engineered postbiotics nanoparticles can effectively suppress macrophage inflammatory activation, modulate the redox balance, and regulate the composition of the gut microbiota, thereby restoring epithelial barriers, inhibiting bacterial invasion, and down-reg

SUBMITTER: Yu T 

PROVIDER: S-EPMC11686147 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature